ジョンソンエンドジョンソンは、木曜日にYellow Jersey Therapeuticsの買収が約12.5億ドルの費用をもたらすことを発表しました。
Zhong Tong Finance learned that Johnson & Johnson (JNJ.US) announced on Thursday that its recently announced acquisition of Yellow Jersey Therapeutics will have an impact on its 2024 third-quarter and full-year results of approximately $1.25 billion. When announcing the financial impact of the transaction, the company said that the transaction is considered an asset acquisition and will generate approximately $1.25 of research and development expenses (R&D) this year. It will also dilute adjusted earnings per share by approximately $0.56 and $0.10 for the company in 2024 and 2025, respectively. Johnson & Johnson plans to revise its guidance to reflect the impact of 2024, and its financial report for the second quarter of 2024 is expected to be released next week.
スイスの製薬会社Numab Therapeuticsは、今年5月に強生が子会社のYellow Jersey Therapeuticsを総額12.5億ドルで現金買収することに合意したことを発表し、アトピー性皮膚炎候補薬NM26の開発などのビジネスを含むものでした。契約に基づき、強生は、特定の疾患に対するNM26治療の開発、製造、商業化の権利を取得しました。この取引は、2024年下半期に完了する見込みでした。
Johnson & Johnson announced on Thursday that the transaction has been successfully completed and a separate agreement has been reached with Kaken Pharmaceutical Co., Ltd. to ensure the right to use NM26 in the Asia-Pacific region.